AFT Pharma Reaches Licensing Agreement for Pascomer® in North America
(WorldNews Asia)

July 22, 2019 AFT Pharma Reaches Licensing Agreement for Pascomer® in North America Key points: o Clinical trials to commence in research centres in five countries, including the world-renowned Mayo Clinic. o The drug is a treatment for Facial Angiofibromas in Tuberous Sclerosis; a market which could potentially be worth US$300+ million in the USA. o AFT takes 100% control of Dermatology Specialty Limited Partnership (DSLP) the joint venture set up to develop Pascomer as part of the agreement. AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has reached an out-licensing and development agreement with US-based Timber Pharmaceuticals [Timber] for the USA, Canada & Mexico for its orphan drug